Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?It highlights possible caries and periapical radiolucencies, and helps measure bone levels, while a dentist or dental specialist reviews the radiograph.
Which images and patients are in scope?It supports extraoral and intraoral 2D dental radiographs, including bitewing, periapical, and panoramic images, for patients aged 22 years or older without remaining primary teeth.
Who uses it?Dental professionals, including dentists and dental specialists, use the output as second-reader support during dental radiograph interpretation.
What does the software produce?It produces highlighted regions and per-tooth bone-level measurements, with PDF and DICOM secondary-capture reporting described in the FDA comparison.
What is its most important limitation?It is an adjunct, not a replacement for complete clinician review, clinical judgment, patient history, or other relevant information.
Clinical takeaway. Denti.AI Detect adds second-reader highlights and bone-level measurement support for labeled adult dental radiographs; the dental professional remains responsible for the interpretation and care decision.
Evidence takeaway. The FDA package reports separate standalone, bone-measurement, and reader-study endpoints. A 24-reader study reported aided wAFROC 0.809 versus 0.784 unaided; this reader-study result is distinct from the standalone detection and bone-measurement endpoints.
Additional limitations
The FDA material describes cloud-based image processing and PDF or DICOM result return, but it does not establish current PACS compatibility, security controls, hosting boundaries, training, pricing, or reimbursement.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Second-reader CADe support for detecting/highlighting caries and periapical radiolucency and for measuring mesial and distal bone levels on extraoral and intraoral 2D dental radiographs in adults aged 22 years and older without remaining primary dentition.
Extraoral and intraoral 2D dental radiographs, including bitewing, periapical, and panoramic images, from patients aged 22 years and older without remaining primary dentition; listed formats include JPEG, JPG, TIFF, TIF, PNG, BMP, and DICOM.
Highlighted ROIs for caries and periapical radiolucency and mesial/distal bone-level measurements for each tooth, with DICOM secondary-capture/PDF reporting described in the device comparison.
The device is an adjunct and does not replace complete clinician review or clinical judgment using the image, patient history, and other relevant information; use is limited to patients aged 22 years and older without remaining primary dentition. The periapical CEJ-Bone specificity acceptance criterion was the one listed exception in the bone-measurement study.
FDA packet: stand-alone caries/periapical-radiolucency testing used 709 images from 6 U.S. sites with three independent dentists and achieved across-category wAFROC AUC 0.737 (95% CI 0.713-0.761) against a prespecified 0.6 lower-bound threshold. Bone-measurement testing used 193 images from 9 U.S. sites with three independent dentists: bitewing CEJ-Bone sensitivity/specificity 98.1%/93.0%, periapical CEJ-Bone 98.2%/88.5%, periapical CEJ-Root 96.9%/92.2%, and extraoral CEJ-Bone-Root 91.6%/84.3%, with task-specific MAEs. A 24-reader, 154-image MRMC study reported aided wAFROC 0.809 versus unaided 0.784 (difference 0.025, p=0.029).
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: stand-alone caries/periapical-radiolucency testing used 709 images from 6 U.S. sites with three independent dentists and achieved across-category wAFROC AUC 0.737 (95% CI 0.713-0.761) against a prespecified 0.6 lower-bound threshold. Bone-measurement testing used 193 images from 9 U.S. sites with three independent dentists: bitewing CEJ-Bone sensitivity/specificity 98.1%/93.0%, periapical CEJ-Bone 98.2%/88.5%, periapical CEJ-Root 96.9%/92.2%, and extraoral CEJ-Bone-Root 91.6%/84.3%, with task-specific MAEs. A 24-reader, 154-image MRMC study reported aided wAFROC 0.809 versus unaided 0.784 (difference 0.025, p=0.029).
These are separately labeled bone-measurement endpoints; the caries/periapical stand-alone detection result is wAFROC AUC, and MAE/reader-study endpoints remain distinct.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Denti.AI Detect regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K230144
Samplen=902
Sites15
IndependenceIndependence not established
K230144
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K230144. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Extraoral and intraoral 2D dental radiographs, including bitewing, periapical, and panoramic images, from patients aged 22 years and older without remaining primary dentition; listed formats include JPEG, JPG, TIFF, TIF, PNG, BMP, and DICOM.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes a cloud-based software-only device accepting the listed image formats and returning a PDF report and DICOM secondary capture to PACS; exact PACS interface versions and local compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the Denti.AI Detect platform as cloud-based in the subject-device column of its technological comparison table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Platform Cloud-based Windows 7 Cloud-based Imaging Intraoral (bitewing," … "Subject Device Primary Predicate Secondary Predicate Device Device". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Highlighted ROIs for caries and periapical radiolucency and mesial/distal bone-level measurements for each tooth, with DICOM secondary-capture/PDF reporting described in the device comparison.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Highlighted ROIs for caries and periapical radiolucency and mesial/distal bone-level measurements for each tooth, with DICOM secondary-capture/PDF reporting described in the device comparison.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Denti.AI Detect platform as cloud-based in the subject-device column of its technological comparison table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Platform Cloud-based Windows 7 Cloud-based Imaging Intraoral (bitewing," … "Subject Device Primary Predicate Secondary Predicate Device Device". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes a cloud-based software-only device accepting the listed image formats and returning a PDF report and DICOM secondary capture to PACS; exact PACS interface versions and local compatibility are not established.
ACR AI Central provides an exact-submission model card for Denti.AI Detect; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-09Last searched
25Fields reviewed
9Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K230144 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Authorized purpose: Aids dentists reviewing bitewing and periapical radiographs of permanent teeth by detecting/segmenting caries and periapical radiolucencies, identifying restorations and dental anatomy, and measuring mesial/distal bone levels; it does not replace dentist review.
Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.